Najjar-Debbiny, 180,351 patient paxlovid early treatment study: 46% lower severe cases [p=0.0002] https://c19p.org/najjardebbiny
copied to clipboard
Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac443
Retrospective 180,351 patients in Israel, 4,737 treated with paxlovid, showing significantly lower combined severe COVID-19 / mortality with treatment.
|
risk of severe case or mortality, 46.0% lower, HR 0.54, p < 0.001, treatment 4,737, control 175,614, adjusted per study, multivariable, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Najjar-Debbiny et al., 6/2/2022, retrospective, Israel, Middle East, peer-reviewed, 8 authors, study period 1 January, 2022 - 28 February, 2022.
Contact:
ronzana@clalit.org.il, ronza.najjar@gmail.com.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.